N-benzyladriamycin-14-valerate (AD 198)

A non-cardiotoxic anthracycline that is cardioprotective through PKC-ε activation

Polly Hofmann, Mervyn Israel, Yoshihiro Koseki, Jeffrey Laskin, Joshua Gray, Aleksandra Janik, Trevor W. Sweatman, Leonard Lothstein

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed in our laboratories that demonstrates cytotoxic superiority over doxorubicin (Adriamycin; DOX) through its circumvention of multiple mechanisms of drug resistance. This characteristic is attributed at least partly to the principal cellular action of AD 198: PKC activation through binding to the C1b (diacylglycerol binding) regulatory domain. A significant dose-limiting effect of DOX is chronic, dose-dependent, and often irreversible cardiotoxicity ascribed to the generation of reactive oxygen species (ROS) from the semiquinone ring structure of DOX. Despite the incorporation of the same ring structure in AD 198, we hypothesized that AD 198 might also be cardioprotective through its ability to activate PKC-ε, a key component of protective ischemic preconditioning in cardiomyocytes. Chronic administration of fractional LD 50 doses of DOX and AD 198 to mice results in histological evidence of dose-dependent ventricular damage by DOX but is largely absent from AD 198-treated mice. The absence of significant cardiotoxicity with AD 198 occurs despite the equal ability of DOX and AD 198 to generate ROS in primary mouse cardiomyocytes. Excised rodent hearts perfused with AD 198 prior to hypoxia induced by vascular occlusion are protected from functional impairment to an extent comparable to preconditioning ischemia. AD 198-mediated cardioprotection correlates with increased PKC-ε activation and is inhibited in hearts from PKC-ε knockout mice. These results suggest that, despite ROS production, the net cardiac effect of AD 198 is protection through activation of PKC-ε.

Original languageEnglish (US)
Pages (from-to)658-664
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume323
Issue number2
DOIs
StatePublished - Nov 1 2007

Fingerprint

Anthracyclines
Protein Kinase C
Reactive Oxygen Species
Cardiac Myocytes
Doxorubicin
N-benzyladriamycin-14-valerate
Ischemic Preconditioning
Diglycerides
Multiple Drug Resistance
Knockout Mice
Blood Vessels
Rodentia
Ischemia

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

N-benzyladriamycin-14-valerate (AD 198) : A non-cardiotoxic anthracycline that is cardioprotective through PKC-ε activation. / Hofmann, Polly; Israel, Mervyn; Koseki, Yoshihiro; Laskin, Jeffrey; Gray, Joshua; Janik, Aleksandra; Sweatman, Trevor W.; Lothstein, Leonard.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 323, No. 2, 01.11.2007, p. 658-664.

Research output: Contribution to journalArticle

Hofmann, Polly ; Israel, Mervyn ; Koseki, Yoshihiro ; Laskin, Jeffrey ; Gray, Joshua ; Janik, Aleksandra ; Sweatman, Trevor W. ; Lothstein, Leonard. / N-benzyladriamycin-14-valerate (AD 198) : A non-cardiotoxic anthracycline that is cardioprotective through PKC-ε activation. In: Journal of Pharmacology and Experimental Therapeutics. 2007 ; Vol. 323, No. 2. pp. 658-664.
@article{45758240c7a74d9e9a98a3f3bfa8e931,
title = "N-benzyladriamycin-14-valerate (AD 198): A non-cardiotoxic anthracycline that is cardioprotective through PKC-ε activation",
abstract = "N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed in our laboratories that demonstrates cytotoxic superiority over doxorubicin (Adriamycin; DOX) through its circumvention of multiple mechanisms of drug resistance. This characteristic is attributed at least partly to the principal cellular action of AD 198: PKC activation through binding to the C1b (diacylglycerol binding) regulatory domain. A significant dose-limiting effect of DOX is chronic, dose-dependent, and often irreversible cardiotoxicity ascribed to the generation of reactive oxygen species (ROS) from the semiquinone ring structure of DOX. Despite the incorporation of the same ring structure in AD 198, we hypothesized that AD 198 might also be cardioprotective through its ability to activate PKC-ε, a key component of protective ischemic preconditioning in cardiomyocytes. Chronic administration of fractional LD 50 doses of DOX and AD 198 to mice results in histological evidence of dose-dependent ventricular damage by DOX but is largely absent from AD 198-treated mice. The absence of significant cardiotoxicity with AD 198 occurs despite the equal ability of DOX and AD 198 to generate ROS in primary mouse cardiomyocytes. Excised rodent hearts perfused with AD 198 prior to hypoxia induced by vascular occlusion are protected from functional impairment to an extent comparable to preconditioning ischemia. AD 198-mediated cardioprotection correlates with increased PKC-ε activation and is inhibited in hearts from PKC-ε knockout mice. These results suggest that, despite ROS production, the net cardiac effect of AD 198 is protection through activation of PKC-ε.",
author = "Polly Hofmann and Mervyn Israel and Yoshihiro Koseki and Jeffrey Laskin and Joshua Gray and Aleksandra Janik and Sweatman, {Trevor W.} and Leonard Lothstein",
year = "2007",
month = "11",
day = "1",
doi = "10.1124/jpet.107.126110",
language = "English (US)",
volume = "323",
pages = "658--664",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - N-benzyladriamycin-14-valerate (AD 198)

T2 - A non-cardiotoxic anthracycline that is cardioprotective through PKC-ε activation

AU - Hofmann, Polly

AU - Israel, Mervyn

AU - Koseki, Yoshihiro

AU - Laskin, Jeffrey

AU - Gray, Joshua

AU - Janik, Aleksandra

AU - Sweatman, Trevor W.

AU - Lothstein, Leonard

PY - 2007/11/1

Y1 - 2007/11/1

N2 - N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed in our laboratories that demonstrates cytotoxic superiority over doxorubicin (Adriamycin; DOX) through its circumvention of multiple mechanisms of drug resistance. This characteristic is attributed at least partly to the principal cellular action of AD 198: PKC activation through binding to the C1b (diacylglycerol binding) regulatory domain. A significant dose-limiting effect of DOX is chronic, dose-dependent, and often irreversible cardiotoxicity ascribed to the generation of reactive oxygen species (ROS) from the semiquinone ring structure of DOX. Despite the incorporation of the same ring structure in AD 198, we hypothesized that AD 198 might also be cardioprotective through its ability to activate PKC-ε, a key component of protective ischemic preconditioning in cardiomyocytes. Chronic administration of fractional LD 50 doses of DOX and AD 198 to mice results in histological evidence of dose-dependent ventricular damage by DOX but is largely absent from AD 198-treated mice. The absence of significant cardiotoxicity with AD 198 occurs despite the equal ability of DOX and AD 198 to generate ROS in primary mouse cardiomyocytes. Excised rodent hearts perfused with AD 198 prior to hypoxia induced by vascular occlusion are protected from functional impairment to an extent comparable to preconditioning ischemia. AD 198-mediated cardioprotection correlates with increased PKC-ε activation and is inhibited in hearts from PKC-ε knockout mice. These results suggest that, despite ROS production, the net cardiac effect of AD 198 is protection through activation of PKC-ε.

AB - N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed in our laboratories that demonstrates cytotoxic superiority over doxorubicin (Adriamycin; DOX) through its circumvention of multiple mechanisms of drug resistance. This characteristic is attributed at least partly to the principal cellular action of AD 198: PKC activation through binding to the C1b (diacylglycerol binding) regulatory domain. A significant dose-limiting effect of DOX is chronic, dose-dependent, and often irreversible cardiotoxicity ascribed to the generation of reactive oxygen species (ROS) from the semiquinone ring structure of DOX. Despite the incorporation of the same ring structure in AD 198, we hypothesized that AD 198 might also be cardioprotective through its ability to activate PKC-ε, a key component of protective ischemic preconditioning in cardiomyocytes. Chronic administration of fractional LD 50 doses of DOX and AD 198 to mice results in histological evidence of dose-dependent ventricular damage by DOX but is largely absent from AD 198-treated mice. The absence of significant cardiotoxicity with AD 198 occurs despite the equal ability of DOX and AD 198 to generate ROS in primary mouse cardiomyocytes. Excised rodent hearts perfused with AD 198 prior to hypoxia induced by vascular occlusion are protected from functional impairment to an extent comparable to preconditioning ischemia. AD 198-mediated cardioprotection correlates with increased PKC-ε activation and is inhibited in hearts from PKC-ε knockout mice. These results suggest that, despite ROS production, the net cardiac effect of AD 198 is protection through activation of PKC-ε.

UR - http://www.scopus.com/inward/record.url?scp=35548973458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548973458&partnerID=8YFLogxK

U2 - 10.1124/jpet.107.126110

DO - 10.1124/jpet.107.126110

M3 - Article

VL - 323

SP - 658

EP - 664

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -